Denali Therapeutics GAAP EPS of -$0.78 misses by $0.09
Source: SeekingAlpha
2025-05-06 17:05:00 ET
More on Denali Therapeutics
- Denali Therapeutics: Vast Pipeline, First Approval Up Ahead
- Denali Therapeutics closes down 11% as 2025 operating expenses seen weighing
- Seeking Alpha’s Quant Rating on Denali Therapeutics
- Historical earnings data for Denali Therapeutics
- Financial information for Denali Therapeutics
Read the full article on Seeking Alpha
For further details see:
Denali Therapeutics GAAP EPS of -$0.78 misses by $0.09
Denali Therapeutics Inc.
NASDAQ: DNLI
DNLI Trading
-1.27% G/L:
$20.25 Last:
349,466 Volume:
$20.91 Open:
DNLI Latest News
February 26, 2026 04:01:00 pm
Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
February 19, 2026 08:30:00 am
Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development
DNLI Stock Data
$3,127,833,066
136,297,507
0.26%
87
N/A
Biotechnology & Life Sciences
Healthcare
US
South San Francisco
